Smoother: a unified and modular framework for incorporating structural dependency in spatial omics data.

Authors:
Su J; Reynier JB; Fu X; Zhong G; Jiang J and 6 more

Journal:
Genome Biol

Publication Year: 2023

DOI:
10.1186/s13059-023-03138-x

PMCID:
PMC10726548

PMID:
38110959

Journal Information

Full Title: Genome Biol

Abbreviation: Genome Biol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Genetics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
5/6
83.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"all public datasets analyzed in this study are available on zenodo [ 71 ] ( https://zenodo org/records/10223862 ). availability of data and materials the python package smoother tutorials and scripts used to simulate st data are publicly available on github [ 69 ] ( https://github com/jiayusupku/smoother/ ) under the bsd 3-clause license."

Evidence found in paper:

"smoother is publicly available as a python package ( https://github com/jiayusupku/smoother/ ).; availability of data and materials the python package smoother tutorials and scripts used to simulate st data are publicly available on github [ 69 ] ( https://github com/jiayusupku/smoother/ ) under the bsd 3-clause license.; all additional analysis scripts for reproducing results and figures presented in this study are available on github [ 70 ] ( https://github com/jiayusupku/smoother_paper/ ) under the mit license."

Evidence found in paper:

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsR. R. is the founder of GenoTwin and member of the Scientific Advisory Board of Diatech Pharmacogenetics and Flahy. B. I. is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca and Merck, and has received research funding to Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore, Regeneron, and Synthekine. None of these activities is related to the results in the current manuscript. Competing interests R. R. is the founder of GenoTwin and member of the Scientific Advisory Board of Diatech Pharmacogenetics and Flahy. B. I. is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca and Merck, and has received research funding to Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore, Regeneron, and Synthekine. None of these activities is related to the results in the current manuscript."

Evidence found in paper:

"Funding This work was funded by the National Institutes of Health, National Cancer Institute (R35CA253126, U01CA261822, and U01CA243073 to R. R. and X. F., R37CA258829 and R21CA263381 to B. I.), the Center for Integrated Cellular Analysis (RM1HG011014 to J. S. and R. R.), and the Edward P. Evans Center for MDS at Columbia University (to J. S. and R. R.). B. I. is supported by National Institute of Health grants, R37CA258829, R01CA280414, R01CA266446, U54CA274506, and additional by the Pershing Square Sohn Cancer Research Alliance Award, the Burroughs Wellcome Fund Career Award for Medical Scientists; a Tara Miller Melanoma Research Alliance Young Investigator Award; the Louis V. Gerstner, Jr. Scholars Program; and the V Foundation Scholars Award."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025